The COVID-19 in athletes (COVA) study: a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The COVID-19 in athletes (COVA) study : a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes. / Rasmusen, Hanne Kruuse; Aarøe, Mikkel; Madsen, Christoffer Valdorff; Gudmundsdottir, Helga Lillian; Mertz, Kenneth Hudlebusch; Mikkelsen, Astrid Duus; Dall, Christian Have; Brushøj, Christoffer; Andersen, Jesper Løvind; Vall-Lamora, Maria Helena Dominguez; Bovin, Ann; Magnusson, S. Peter; Thune, Jens Jakob; Pecini, Redi; Pedersen, Lars.

I: European Clinical Respiratory Journal, Bind 10, Nr. 1, 2149919, 2023.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Rasmusen, HK, Aarøe, M, Madsen, CV, Gudmundsdottir, HL, Mertz, KH, Mikkelsen, AD, Dall, CH, Brushøj, C, Andersen, JL, Vall-Lamora, MHD, Bovin, A, Magnusson, SP, Thune, JJ, Pecini, R & Pedersen, L 2023, 'The COVID-19 in athletes (COVA) study: a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes', European Clinical Respiratory Journal, bind 10, nr. 1, 2149919. https://doi.org/10.1080/20018525.2022.2149919

APA

Rasmusen, H. K., Aarøe, M., Madsen, C. V., Gudmundsdottir, H. L., Mertz, K. H., Mikkelsen, A. D., Dall, C. H., Brushøj, C., Andersen, J. L., Vall-Lamora, M. H. D., Bovin, A., Magnusson, S. P., Thune, J. J., Pecini, R., & Pedersen, L. (2023). The COVID-19 in athletes (COVA) study: a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes. European Clinical Respiratory Journal, 10(1), [2149919]. https://doi.org/10.1080/20018525.2022.2149919

Vancouver

Rasmusen HK, Aarøe M, Madsen CV, Gudmundsdottir HL, Mertz KH, Mikkelsen AD o.a. The COVID-19 in athletes (COVA) study: a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes. European Clinical Respiratory Journal. 2023;10(1). 2149919. https://doi.org/10.1080/20018525.2022.2149919

Author

Rasmusen, Hanne Kruuse ; Aarøe, Mikkel ; Madsen, Christoffer Valdorff ; Gudmundsdottir, Helga Lillian ; Mertz, Kenneth Hudlebusch ; Mikkelsen, Astrid Duus ; Dall, Christian Have ; Brushøj, Christoffer ; Andersen, Jesper Løvind ; Vall-Lamora, Maria Helena Dominguez ; Bovin, Ann ; Magnusson, S. Peter ; Thune, Jens Jakob ; Pecini, Redi ; Pedersen, Lars. / The COVID-19 in athletes (COVA) study : a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes. I: European Clinical Respiratory Journal. 2023 ; Bind 10, Nr. 1.

Bibtex

@article{291a3a8bfc5641debbeb301397ec39cb,
title = "The COVID-19 in athletes (COVA) study: a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes",
abstract = "Background: COVID-19 can cause cardiopulmonary involvement. Physical activity and cardiac complications can worsen prognosis, while pulmonary complications can reduce performance. Aims: To determine the prevalence and clinical implications of SARS-CoV-2 cardiopulmonary involvement in elite athletes. Methods: An observational study between 1 July 2020 and 30 June 2021 with the assessment of coronary biomarkers, electrocardiogram, echocardiography, Holter-monitoring, spirometry, and chest X-ray in Danish elite athletes showed that PCR-tested positive for SARS-CoV-2. The cohort consisted of male football players screened weekly (cohort I) and elite athletes on an international level only tested if they had symptoms, were near-contact, or participated in international competitions (cohort II). All athletes were categorized into two groups based on symptoms and duration of COVID-19: Group 1 had no cardiopulmonary symptoms and duration ≤7 days, and; Group 2 had cardiopulmonary symptoms or disease duration >7 days. Results: In total 121 athletes who tested positive for SARS-CoV-2 were investigated. Cardiac involvement was identified in 2/121 (2%) and pulmonary involvement in 15/121 (12%) participants. In group 1, 87 (72%), no athletes presented with signs of cardiac involvement, and 8 (7%) were diagnosed with radiological COVID-19-related findings or obstructive lung function. In group 2, 34 (28%), two had myocarditis (6%), and 8 (24%) were diagnosed with radiological COVID-19-related findings or obstructive lung function. Conclusions: These clinically-driven data show no signs of cardiac involvement among athletes who tested positive for SARS-CoV-2 infection without cardiopulmonary symptoms and duration <7 days. Athletes with cardiopulmonary symptoms or prolonged duration of COVID-19 display, exercise-limiting cardiopulmonary involvement.",
keywords = "Athletes, coronavirus, myocarditis, pulmonary involvement, return-to-sport",
author = "Rasmusen, {Hanne Kruuse} and Mikkel Aar{\o}e and Madsen, {Christoffer Valdorff} and Gudmundsdottir, {Helga Lillian} and Mertz, {Kenneth Hudlebusch} and Mikkelsen, {Astrid Duus} and Dall, {Christian Have} and Christoffer Brush{\o}j and Andersen, {Jesper L{\o}vind} and Vall-Lamora, {Maria Helena Dominguez} and Ann Bovin and Magnusson, {S. Peter} and Thune, {Jens Jakob} and Redi Pecini and Lars Pedersen",
note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2023",
doi = "10.1080/20018525.2022.2149919",
language = "English",
volume = "10",
journal = "European Clinical Respiratory Journal",
issn = "2001-8525",
publisher = "Co-Action Publishing",
number = "1",

}

RIS

TY - JOUR

T1 - The COVID-19 in athletes (COVA) study

T2 - a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes

AU - Rasmusen, Hanne Kruuse

AU - Aarøe, Mikkel

AU - Madsen, Christoffer Valdorff

AU - Gudmundsdottir, Helga Lillian

AU - Mertz, Kenneth Hudlebusch

AU - Mikkelsen, Astrid Duus

AU - Dall, Christian Have

AU - Brushøj, Christoffer

AU - Andersen, Jesper Løvind

AU - Vall-Lamora, Maria Helena Dominguez

AU - Bovin, Ann

AU - Magnusson, S. Peter

AU - Thune, Jens Jakob

AU - Pecini, Redi

AU - Pedersen, Lars

N1 - Publisher Copyright: © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2023

Y1 - 2023

N2 - Background: COVID-19 can cause cardiopulmonary involvement. Physical activity and cardiac complications can worsen prognosis, while pulmonary complications can reduce performance. Aims: To determine the prevalence and clinical implications of SARS-CoV-2 cardiopulmonary involvement in elite athletes. Methods: An observational study between 1 July 2020 and 30 June 2021 with the assessment of coronary biomarkers, electrocardiogram, echocardiography, Holter-monitoring, spirometry, and chest X-ray in Danish elite athletes showed that PCR-tested positive for SARS-CoV-2. The cohort consisted of male football players screened weekly (cohort I) and elite athletes on an international level only tested if they had symptoms, were near-contact, or participated in international competitions (cohort II). All athletes were categorized into two groups based on symptoms and duration of COVID-19: Group 1 had no cardiopulmonary symptoms and duration ≤7 days, and; Group 2 had cardiopulmonary symptoms or disease duration >7 days. Results: In total 121 athletes who tested positive for SARS-CoV-2 were investigated. Cardiac involvement was identified in 2/121 (2%) and pulmonary involvement in 15/121 (12%) participants. In group 1, 87 (72%), no athletes presented with signs of cardiac involvement, and 8 (7%) were diagnosed with radiological COVID-19-related findings or obstructive lung function. In group 2, 34 (28%), two had myocarditis (6%), and 8 (24%) were diagnosed with radiological COVID-19-related findings or obstructive lung function. Conclusions: These clinically-driven data show no signs of cardiac involvement among athletes who tested positive for SARS-CoV-2 infection without cardiopulmonary symptoms and duration <7 days. Athletes with cardiopulmonary symptoms or prolonged duration of COVID-19 display, exercise-limiting cardiopulmonary involvement.

AB - Background: COVID-19 can cause cardiopulmonary involvement. Physical activity and cardiac complications can worsen prognosis, while pulmonary complications can reduce performance. Aims: To determine the prevalence and clinical implications of SARS-CoV-2 cardiopulmonary involvement in elite athletes. Methods: An observational study between 1 July 2020 and 30 June 2021 with the assessment of coronary biomarkers, electrocardiogram, echocardiography, Holter-monitoring, spirometry, and chest X-ray in Danish elite athletes showed that PCR-tested positive for SARS-CoV-2. The cohort consisted of male football players screened weekly (cohort I) and elite athletes on an international level only tested if they had symptoms, were near-contact, or participated in international competitions (cohort II). All athletes were categorized into two groups based on symptoms and duration of COVID-19: Group 1 had no cardiopulmonary symptoms and duration ≤7 days, and; Group 2 had cardiopulmonary symptoms or disease duration >7 days. Results: In total 121 athletes who tested positive for SARS-CoV-2 were investigated. Cardiac involvement was identified in 2/121 (2%) and pulmonary involvement in 15/121 (12%) participants. In group 1, 87 (72%), no athletes presented with signs of cardiac involvement, and 8 (7%) were diagnosed with radiological COVID-19-related findings or obstructive lung function. In group 2, 34 (28%), two had myocarditis (6%), and 8 (24%) were diagnosed with radiological COVID-19-related findings or obstructive lung function. Conclusions: These clinically-driven data show no signs of cardiac involvement among athletes who tested positive for SARS-CoV-2 infection without cardiopulmonary symptoms and duration <7 days. Athletes with cardiopulmonary symptoms or prolonged duration of COVID-19 display, exercise-limiting cardiopulmonary involvement.

KW - Athletes

KW - coronavirus

KW - myocarditis

KW - pulmonary involvement

KW - return-to-sport

U2 - 10.1080/20018525.2022.2149919

DO - 10.1080/20018525.2022.2149919

M3 - Journal article

C2 - 36518348

AN - SCOPUS:85146804677

VL - 10

JO - European Clinical Respiratory Journal

JF - European Clinical Respiratory Journal

SN - 2001-8525

IS - 1

M1 - 2149919

ER -

ID: 366761524